BioInvent International AB (BOVNF)
4.70
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
BioInvent International Net Income (Quarterly): -9.370M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -9.370M |
| June 30, 2024 | -12.87M |
| March 31, 2024 | -7.515M |
| December 31, 2023 | -9.151M |
| September 30, 2023 | -6.588M |
| June 30, 2023 | -8.409M |
| March 31, 2023 | -7.074M |
| December 31, 2022 | -7.314M |
| September 30, 2022 | -6.099M |
| June 30, 2022 | 17.11M |
| March 31, 2022 | -7.272M |
| December 31, 2021 | -8.918M |
| September 30, 2021 | -7.249M |
| June 30, 2021 | -6.816M |
| March 31, 2021 | -9.529M |
| December 31, 2020 | 3.317M |
| September 30, 2020 | -3.714M |
| June 30, 2020 | -4.069M |
| March 31, 2020 | -3.394M |
| December 31, 2019 | -4.264M |
| September 30, 2019 | -3.873M |
| June 30, 2019 | -3.473M |
| March 31, 2019 | -3.031M |
| December 31, 2018 | -3.612M |
| September 30, 2018 | -2.500M |
| Date | Value |
|---|---|
| June 30, 2018 | -4.993M |
| March 31, 2018 | -3.074M |
| December 31, 2017 | -4.001M |
| September 30, 2017 | -2.637M |
| June 30, 2017 | -2.666M |
| March 31, 2017 | -2.503M |
| December 31, 2016 | -0.8057M |
| September 30, 2016 | -3.350M |
| June 30, 2016 | -3.300M |
| March 31, 2016 | 0.0387M |
| December 31, 2015 | -2.482M |
| September 30, 2015 | -2.664M |
| June 30, 2015 | -2.994M |
| March 31, 2015 | -2.616M |
| December 31, 2014 | -3.832M |
| September 30, 2014 | -1.483M |
| June 30, 2014 | 0.563M |
| March 31, 2014 | -2.931M |
| December 31, 2013 | 3.143M |
| September 30, 2013 | -2.265M |
| June 30, 2013 | -1.438M |
| March 31, 2013 | -2.216M |
| December 31, 2012 | -3.226M |
| September 30, 2012 | -5.523M |
| June 30, 2012 | -13.31M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-12.87M
Minimum
Jun 2024
17.11M
Maximum
Jun 2022
-5.459M
Average
-7.161M
Median
Net Income (Quarterly) Benchmarks
| Abliva AB | -2.414M |
| Oncopeptides AB | -3.758M |
| Hansa Biopharma AB | -10.00M |
| BioArctic AB | -6.415M |
| Camurus AB | 12.46M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.23M |
| Total Expenses (Quarterly) | 11.55M |
| EPS Diluted (Quarterly) | -0.1426 |
| Enterprise Value | 215.05M |
| Profit Margin (Quarterly) | -761.8% |
| Earnings Yield | -12.57% |
| Normalized Earnings Yield | -13.37 |